ESC 2024 | SENIOR RITA: Invasive Strategy for Elderly Patients with ACS

Prior studies indicate that up to 50% of these patients with non ST elevation myocardial infarction (NSTEMI) are over 70, and that only 14% patients aged ≥85 receive an angiography. Taking this into account, the British Heart Foundation research team carried out this study. 

It included patients aged ≥75 allocated to either an invasive strategy or a conservative management. Researchers assessed all participants’ frailty, cognitive status and comorbidities both initially and during followup. 

Data from 1,518 patients were collected: 45% were women, 72% were over 80, 80% were classified as pre-frail or frail, 60% scored less than 26 in the Montreal cognitive test and comorbidity Charlson index was mean 5.

The primary outcome, which included cardiovascular death or non-fatal acute myocardial infarction (AMI) did not show significant differences between the groups (HR 0.94; CI95% 0.77-1.14; P=0.53). When looking at the individual components, there were no differences in cardiovascular mortality. However, there was significant reduction in non-fatal AMI in favor of the invasive strategy at mean 4 year followup (HR 0.75; CI95% 0.57-0.99). Reduced rate of new revascularization was also a considerable benefit (HR 0.26; CI95% 0.17-0.39). 

Read also: ESC 2024 | RHEIA Trial: Transcatheter vs. Surgical Replacement in Women.

In elderly patients with type 1 NSTEMI, an invasive strategy resulted safe, even though there was no significant reduction in the combined end point of cardiovascular death and non-fatal MI vs. the conservative strategy. Nevertheless, there was a lower incidence of non-fatal MI and need for new revascularization. 

Presented by Vijay Kunadian in Hot-Line Sessions, ESC Congress 2024, August 30-September 2, Londres, Inglaterra.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

Dr. Omar Tupayachi
Dr. Omar Tupayachi
Member of the Editorial Board of solaci.org

More articles by this author

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...

ACC 2026 | STEMI-Door To Unload: Unloading with Impella before PCI did not reduce infarct size in anterior STEMI

Anterior ST-segment elevation myocardial infarction (STEMI) remains associated with a high incidence of heart failure and mortality, even in the era of early reperfusion....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

ACC 2026 | CHIP-BCIS3: Impella use as support in high-risk complex PCI

The use of percutaneous ventricular support during high-risk complex PCI has been proposed as a strategy to prevent hemodynamic deterioration in patients with severe...

ACC 2026 | ORBITA-CTO: PCI in chronic total occlusions and stable angina — the randomized trial we were missing?

Percutaneous coronary intervention (PCI) for chronic total occlusions (CTO) remains a topic of ongoing debate in stable angina, with persistent uncertainty regarding its role...

ACC 2026 | FAST III: vFFR vs FFR in physiology-guided revascularization of intermediate coronary lesions

Physiological assessment of intermediate coronary lesions remains a cornerstone in decision-making for coronary revascularization. Although FFR continues to be one of the guideline-recommended references,...